GlassScriptPhysician profile
Stephanie A Curry
NPI 1508152778
$7,873.92
in general payments reported to CMS, 2019-2025
45 companies · $38.36 in 2025
The $38.36 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,093 · 2020: $1,189 · 2021: $1,890 · 2022: $1,319 · 2023: $1,557 · 2024: $788 · 2025: $38.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,383 · Education: $0.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,382.97 |
| Education | $0.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,571.18 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,052.94 | 2019-2024 | Mounjaro, Jardiance, Trulicity |
| Abbvie INC. | $940.05 | 2019-2024 | Synthroid, Ubrelvy, Qulipta |
| Sanofi-Aventis U.S. LLC | $603.34 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $549.07 | 2019-2024 | Spiriva Respimat, Jardiance, Stiolto Respimat |
| Janssen Pharmaceuticals, INC | $466.62 | 2019-2024 | Xarelto |
| Exact Sciences Corporation | $261.54 | 2023-2024 | Cologuard Collection Kit |
| Collegium Pharmaceutical, INC. | $243.26 | 2023-2025 | Xtampza, Jornay Pm |
| Astrazeneca Pharmaceuticals LP | $215.72 | 2019-2024 | Farxiga, Airsupra |
| Mannkind Corporation | $214.40 | 2020-2021 | |
| Abbott Laboratories | $157.32 | 2019-2023 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $153.58 | 2019-2024 | Gardasil 9, Verquvo, Varivax |
| Amgen INC. | $101.89 | 2020-2023 | Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $101.14 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $96.91 | 2021 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Curry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.